Fig. 4. SARS-CoV-2 platform development using the MS2-SARS-CoV-2 VLP standard.
a Schematic of the modular platform for the detection of SARS-CoV-2. Viral RNA is isolated using the Analytik Jena FeliX liquid handler with the Analytik Jena or Promega RNA extraction kits. Sample RNA is transferred and detection reactions are set up using the Labcyte Echo platform. These include qPCR, validated for the TaqPath (Thermo Fisher Scientific), Luna (NEB), and Fast Virus (Thermo Fisher Scientific) RT-qPCR master mix options, RT-LAMP nucleic acid detection, and the CRISPR-Cas13a diagnostic workflow. b Automated RNA extraction was developed using VLP dilutions of 103 and 104 copies/mL for the Analytik Jena and Promega RNA extraction kits. Efficiency of the extractions using both kits was analysed by RT-qPCR with the CDC N1 primer–probe set using the TaqPath master mix. c Dilutions of VLPs used for RT-qPCR in b were analysed using the CRISPR NAT to demonstrate the use of this workflow as an alternative diagnostic option. Error bars in b represent mean ± SE of n = 3 biologically independent samples with three technical replicates. Error bars in c represent mean ± SE of n = 3 independent amplification replicates and four technical replicates for CRISPR detection. Source data are available in the Source Data file.